Published in the Journal of Experimental Medicine online Oct. 31, the new study found that
infliximab prevents TNF alpha from speeding the death of Paneth cells, which protect the gut from microbes.
The authors hypothesize that maintaining a target
infliximab concentration
prevents the formation of antibodies to the therapy, which are implicated in loss of response to the drug and infusion reactions.